FDA approves Takeda Gattex for treatment of children with short bowel syndrome over 1 year of age
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In children, SBS is a chronic, life-threatening diseasePatients due to congenital or acquired disease, need surgery to remove most of the intestines, resulting in poor absorption of nutrients and moisturerecently, Takeda(http://announced that the U.SFDA(http://approved the company's Gatex (teduglutide) to expand its use to treat children with short bowel syndrome (SBS) who need intravenous infusion treatmentAbout Gattex
Gattex, adrug(http:// that simulates glucagon-like peptide-2 (GLP-2)It helps the remaining intestines absorb more nutrientspharmacological studies in adult patients have shown that Gattex improves fluid levels absorbed by the gutGattex has been approved for treatment of adult SBS patientsThe studythis approval is based on a 24-week clinicaltrial(http://The results showed that 69% of patients who received 0.05 mg/kg of Gatex treatment per day received more than 20% less ps infusionsPatients received an average 42% less PS infusion than baselineGattex reduced PS infusions by an average of three hours per day, and 12% of patients no longer needed TO receive PS
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
